Study Name:
Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab With or Without Maintenance MK-2870 in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer
Targeted Disease(s):
Lung Cancer
Purpose of Study:
This is a phase 3 study of pembrolizumab in combination with carboplatin/taxane (paclitaxel or nab-paclitaxel) followed by pembrolizumab with or without maintenance sacituzumab tirumotecan (sac-TMT; MK-2870) in first-line treatment of metastatic squamous non-small cell lung cancer.
Study Dates:
June 10, 2024 - January 12, 2029
Type of Study:
Pre-Market
Study Location:
Nationwide
Sponsors:
Merck Sharp & Dohme LLC
Contact:
Phone: 1-888-577-8839
Email: [email protected]
ClinicalTrails.gov Identifier:
NCT06422143
